Page 3 - Merck Sharp News Today

It's the same mRNA technology that was used in coronavirus vaccines.

Trial of personalized mRNA vaccine targets melanoma, offering hope for effective cancer treatment.

Researchers led by Queen Mary University of London and supported by the National Institute for Health and Care Research (NIHR) have discovered over a hundred new regions of the human genome, also known as genomic loci, that appear to influence a person’s blood pressure. In total, over 2,000 independent genetic signals for blood pressure are now reported, demonstrating that blood pressure is a highly complex trait influenced by thousands of different genetic variants.

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Mesoblast (NASDAQ:MESO – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Insider & Institutional Ownership 83.7% of Gilead Sciences shares […]

An international clinical testing a cancer immunotherapy, which may prevent skin cancer from recurring, recruited its 1st patient from UK

Steve Young is part of the tests to see if an mRNA jab can stop the deadliest skin cancer returning.

Steve Young, a British musician, is one of the first people to receive a personalized vaccine intended to prevent his melanoma from ever returning. Currently, melanoma kills nearly 10,000 Americans each year.

25.04.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, ...

Hanmi Pharmaceutical announced it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD . Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1...

Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data